ctDNA analysis in IM011 screening population #EAU24 Matt Galsky podcasters.spotify.com/pod/show/the-u…

Adjuvant nivo #EAU24 Matt Galsky podcasters.spotify.com/pod/show/the-u…

Serial ctDNA testing from IMVIGOR11 (post cystectomy in muscle invasive bladder cancer) show that ctDNA-ve patients (n=171) with a minimum of 12months follow up have 10% relapse rates and almost no deaths #EAU24 . Do we need to give adjuvant therapy to those as such low risk?

Part 2 of bladder sparing approaches in muscle invasive bladder cancer Michiel van der Heijden - new drugs, utDNA, ctDNA and radiotherapy could change everything. Will we need adjuvant therapy? podcasters.spotify.com/pod/show/the-u…

The results of the EV-302 trial, which reported improved OS & DFS for patients with mUC treated with 1L EV+P over chemo, could be 'the moon landing' for anyone who cares for patients with UC. Joshua Meeks explains for #ASCODailyNews : brnw.ch/21wIk4x #gucsm

This one doesn’t disappoint⁩. Crushed a bit by ⁦Matt Galsky⁩ biomarker comment “if you know the future predicting the future isn’t helpful” ⁦Tom Powles⁩ ⁦⁦Brian Rini, MD⁩ podcasts.apple.com/us/podcast/the…

Easter paper of the month with Matt Galsky - gem/cis/nivo with bladder sparing approaches and single agent nivo in responders. Magic data. Move to a cystectomy free era I hope . Nature Medicine podcasters.spotify.com/pod/show/the-u…

Oncology Brothers Karine Tawagi MD Sia Daneshmand, M.D. CancerNetwork® Bijoy Telivala Yakup Ergün Andrea Apolo, M.D. Santhosh Ambika Amanda Nizam, MD Petros Grivas Shilpa Gupta Enrique Grande Paulo G Bergerot The ESMO guidlines recommends EVP as the preferred standard of care, while nivo/cis and maintenance avelumab are interchangeable and recommended when EVP is not available or contraindicated

Join us at the 2024 World Conference on GU cancers in New York this August. We look forward to hosting a Featured Session at this 2-day CE meeting and sharing the stage with world-renowned thought leaders. Register at: worldguconference.com World GU Conference #WorldGU24

Very happy to see this in print! Congratulations to all involved in this transformative effort, and to the patients who may benefit from this combination therapy.

EV and pembrolizumab doubling PFS and OS in 1st line UC compared to chemotherapy NEJM

A short and effective video summarising the EV302 study in 1st line advanced bladder cancer. It shows enfortumab vedotin significantly outperforming standard chemotherapy and changing the standard of care in this lethal disease NEJM nejm.org/do/10.1056/NEJ…

The 3rd Annual #UromigosLive conference will be in Nashville September 27/28. Amazing faculty including Petros Grivas Matt Galsky Shilpa Gupta Toni Choueiri, MD Tanya Dorff Hans Hammers Laurence Albiges Tian Zhang, MD, MHS Michael Morris and more!! Rising Stars, Uromigos Cup and some surprises! MashupMD

Our 300th podcast discussing the controvacies in adjuvant therapy, the importance of OS, subsequent therapy, trial design and risk in bladder and renal cancer with David McDermott. Thanks for listening . Feel free to help us with feedback. anchor.fm/the-uromigos/e…

Dana Rathkopf describes her data on the androgen receptor ligand-directed degrader BMS-986365 anchor.fm/the-uromigos/e…

Updated table of IO combos (ITT population) in front line mRCC after #ASCOGU24 . Has anything changed for you based on these data?

Have a listen to Andrea Apolo, M.D. described the results of the adjuvant pembro trial. anchor.fm/the-uromigos/e…

Come join this CME session with Sumanta K. Pal, MD, FASCO Pedro C Barata, MD MSc FACP #DavidMcDermott @uromigos and myself!
This Thursday 1/25 6pm
Marriott Marquis Yerba Buena
In tandem ASCO #GU24

Thank you for getting us to 300,000 total listens!!

#ASCOGU24 podcasts coming soon..

Estamos iniciando una serie de podcasts en español, Las Tres Amigas con Begoña, Cristina y Elena Elena Castro Cris Bego PValderrama. Esperamos que os gusten. Aquí está el enlace al primer podcast. Brian Rini, MD Enrique Grande Tom Powles Daniel Castellano anchor.fm/the-uromigos/e…